NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
Clinical Trials
43 trialsNCT06486883 2026-04-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT07427394 2026-02-23
SERENA-1b
AstraZeneca
Phase 2 Not yet recruiting
NCT07359404 2026-01-22
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Enrolling by invitation
NCT07259226 2025-12-02
OASIS
UNICANCER
Phase 2 Recruiting
NCT05530057 2025-11-20
ESPERO
Seoul National University Hospital
Phase 2 Recruiting
NCT07130383 2025-11-18
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 2 Recruiting
NCT07180082 2025-11-18
CORIN-PYRA
RenJi Hospital
Phase 2 Recruiting
NCT07180160 2025-11-18
ITHRAN
RenJi Hospital
Phase 2 Recruiting
NCT07125950 2025-08-15
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT04227327 2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2 Terminated
NCT07083505 2025-07-24
A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT07041437 2025-06-27
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT04892693 2025-04-17
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Seoul National University Hospital
Phase 2 Recruiting
NCT05536128 2025-04-17
Post-CDK
Seoul National University Hospital
Phase 2 Recruiting
NCT06750848 2024-12-27
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
Affiliated Cancer Hospital of Shantou University Medical College
Phase 2 Not yet recruiting
NCT06470672 2024-12-20
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06656624 2024-10-24
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03205761 2024-10-18
COMETABreast
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT06176534 2024-08-20
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase â…¡ Clinical Trial
Henan Cancer Hospital
Phase 2 Recruiting
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT06433609 2024-05-30
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Beijing GoBroad Hospital
Phase 2 Not yet recruiting
NCT06339281 2024-04-19
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06375707 2024-04-19
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06125834 2024-04-16
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06354114 2024-04-09
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT05085002 2024-03-12
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT04714619 2023-12-19
CAILA
MedSIR
Phase 2 Terminated
NCT04304352 2023-06-28
VEX
European Institute of Oncology
Phase 2 Unknown
NCT03025880 2023-04-03
PANGEA
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT03931551 2023-02-22
OPHELIA
MedSIR
Phase 2 Terminated
NCT05469750 2022-07-22
Dalpiciclib Plus Letrozole and Capecitabine
Fujian Medical University Union Hospital
Phase 2 Unknown
NCT05431504 2022-06-24
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT03071926 2022-04-20
Metronomic PLD in Patients With Primary Endocrine Resistant ABC
Fudan University
Phase 2 Unknown
NCT05255523 2022-02-24
Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer
Fujian Medical University Union Hospital
Phase 2 Unknown
NCT05020964 2021-08-25
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib
ChineseAMS
Phase 2 Unknown
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT03405168 2018-11-16
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT02069093 2017-02-13
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Novartis
Phase 2 Completed
NCT00494481 2016-09-30
E3 Breast Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT00754325 2016-05-26
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
Phase 2 Completed
NCT00717951 2008-07-25
A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer
Academy Military Medical Science, China
Phase 2 Unknown